News
Resivant Medical Receives U.S. Patent Protecting Novel Single-Lever, Single-Handed Applicator at the Core of the Cutiva™ PLUS Skin Closure System
Akron, Ohio | September 22, 2026 | PRNewswire
Resivant Medical announced today that the U.S. Patent and Trademark Office has issued Patent No. 12,678,148, covering the novel single-lever, single-handed applicator design at the core of the Cutiva™ PLUS Skin Closure System. The patent protects the mechanism that allows clinicians to start, control, and stop the flow of adhesive using a single lever, without repositioning the hand or device.
“This applicator lets a surgeon control adhesive flow with one simple motion of the hand to start it, stop it, and start it again, all with complete precision. The glass ampoule is broken by the lever system and not by the surgeon’s fingers,” said David Kay, MD FAAOS, founder of Resivant Medical. “Combined with our high-viscosity, no-run adhesive, it gives clinicians a level of control during closure that simply hasn’t existed before.”
The patented design uses a pivoting lever that acts directly on the adhesive ampoule, generating controlled pressure to dispense adhesive when depressed and immediately halting flow when released. Paired with the Cutiva™ high-viscosity, no-run liquid adhesive, the applicator enables precise, intermittent dosing and clean, single-handed application that supports reliable wound closure, which are hallmarks of the Cutiva™ PLUS Skin Closure System. The System is cleared by the US FDA and is available and being used across the United States.
This issuance adds to Resivant’s growing intellectual property portfolio of issued and pending patents covering both its proprietary adhesive chemistry and delivery technology.
About Resivant Medical:
Resivant Medical is developing next-generation medical adhesive technologies designed to enhance wound closure for patients and healthcare professionals. Its portfolio of skin closure adhesive products is designed for topical application on wounds and surgical incisions.
For more information, visit www.resivant.com.
Email: investors@resivant.com
Media Contact:
Lindsey Dinneen
Director of Marketing & Engagement
Project Medtech
lindsey.dinneen@projectmedtech.com
Resivant Medical Successfully Completes First Patient Cases with Cutiva™ PLUS Skin Closure System, Marking First Human Use of a Silicone Cyanoacrylate
Akron, Ohio | August 18, 2026 | PRNewswire
Resivant Medical today announced the first patient uses of its Cutiva™ PLUS Skin Closure System, marking the first use of its proprietary Cutiva™ siliconized adhesive platform. This represents the first clinical use of a new cyanoacrylate chemistry in topical skin adhesives since the introduction of 2-octyl cyanoacrylate more than two decades ago.
Resivant’s proprietary Cutiva™ adhesive features an innovative formulation that merges the high-strength bond of super glue with the advantages of crosslinked silicone rubber. The outcome is a skin adhesive that provides robust wound closure, enhanced flexibility, durability, and improved patient safety and comfort.
The milestone procedures were performed June 22 and June 23, 2026 by David Friscia, MD, an orthopaedic foot and ankle surgeon at Eisenhower Health in Rancho Mirage, California, with all cases proceeding without complication. This milestone follows the successful transfer of Resivant’s proprietary adhesive chemistry to commercial-scale manufacturing, enabling initial clinical use and supporting continued investment to expand production capacity ahead of a broader market launch.
“Seeing Cutiva™ PLUS used successfully in patients for the first time is a defining milestone for Resivant Medical,” said Darren Obrigkeit, CEO of Resivant Medical. “Developing an entirely new adhesive chemistry, and successfully scaling it for commercial manufacturing, is the result of years of scientific, engineering, and operational work. We’re incredibly grateful to Dr. Friscia and the team at Eisenhower Health for their partnership and look forward to expanding clinical use as we prepare for broader commercialization.”
“Cutiva™ PLUS performed exactly as expected in the operating room,” said Dr. Friscia. “Incision sites in foot and ankle surgery are under constant mechanical stress, so closure durability matters as much as the initial result. The applicator gave me precise placement, and the mesh added reinforcement I don’t get with a topical adhesive alone.”
Cutiva™ PLUS combines a high-viscosity, no-run liquid adhesive with a surgical mesh patch, dispensed from a single-handed applicator for controlled, precise application. Unlike traditional topical skin adhesives, Cutiva™ PLUS Skin Closure System has been designed to minimize the potential for skin reactions while supporting patient comfort. The adhesive forms a protective microbial barrier over the incision without the need for additional dressings, and the mesh allows for easy removal without damaging the surrounding skin. These benefits make Cutiva™ PLUS well suited to a wide range of surgical specialties, supporting strong wound closure with enhanced flexibility, durability, and patient comfort.
Additional clinical sites are actively onboarding Cutiva™ PLUS, with expanded clinical experience and additional case results expected in the coming months as Resivant continues preparations for broader commercialization. The technology originated from foundational adhesive research at the University of Akron and is protected by a growing intellectual property portfolio.
About Resivant Medical:
Resivant Medical is developing next-generation medical adhesive technologies designed to enhance wound closure for patients and healthcare professionals. Its portfolio of skin closure adhesive products is designed for topical application on wounds and surgical incisions.
For more information, visit www.resivant.com.
Email: investors@resivant.com
Media Contact:
Lindsey Dinneen
Director of Marketing & Engagement
Project Medtech
lindsey.dinneen@projectmedtech.com
Resivant Medical Receives FDA Clearance for Two Novel High-Viscosity Tissue Adhesive Products Cutiva™ Topical Skin Adhesive and Cutiva™ PLUS Skin Closure System
Akron, Ohio | August 23, 2024 | PRNewswire
Resivant Medical announced today it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its first two products, Cutiva™ Topical Skin Adhesive, and Cutiva PLUS™ Skin Closure System, which combines an adhesive mesh patch with high-viscosity Cutiva™ liquid adhesive. This achievement represents a significant advancement in medical tissue adhesive and wound closure technology and marks the first major adhesive advancement in over 25 years.
“The Cutiva platform signifies a fundamental breakthrough in cyanoacrylate adhesive technology for surgical incision and traumatic laceration closure. Cutiva adhesive’s unique chemistry maintains a clean incision site without the need for additional dressings and is formulated to significantly reduce the level of exposure to skin irritants,” says Darren Obrigkeit, CEO, Resivant Medical.
Resivant’s proprietary Cutiva adhesive features an innovative formulation that merges the high-strength bond of super glue with the advantages of crosslinked silicone rubber. The outcome is a skin adhesive that provides robust wound closure, enhanced flexibility, durability, and improved patient safety and comfort.
All Cutiva products are dispensed from a new, easy-to-use, single-handed applicator and form a protective microbial barrier over the incision. The high-viscosity, no-run liquid adhesive remains in place, preventing unwanted spreading and ensuring controlled application. The Cutiva PLUS system, comprised of surgical mesh and the novel adhesive, allows for easy removal without damaging the surrounding skin and is suitable for a wide range of surgical specialties.
About Resivant Medical:
Resivant Medical, a pioneer in the field of medical adhesives, has developed groundbreaking adhesive technology that enhances usability and performance for both patients and healthcare professionals. Its range of skin closure adhesive products is designed for topical application on wounds and surgical incisions. The global skin closure market, encompassing both traditional and advanced surgical closure methods, is valued at approximately USD $6.2 billion in 2024 and is anticipated to experience significant growth in the coming years.